ADRB2 and Parkinson disease: In our study, for repurposing β2AR agonist, FMT as anti-Parkinson agent, an effort has been made to prepare and evaluate FMT as SLNs surface modified with PS-80 (FMT-SLNs-PS80) in order to achieve brain specific delivery and avoid the peripheral side effects for the management of PD.